<DOC>
	<DOC>NCT00892502</DOC>
	<brief_summary>The purpose of this study is to determine whether treatment with Bismuth can reduce the toxicity of chemotherapy and radiotherapy in patients with malignant diseases of the blood.</brief_summary>
	<brief_title>Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Bismuth</mesh_term>
	<criteria>Patients of 18 years or over referred to the Department of Haematology L, Herlev Hospital, with a view to 'cytostatic'? treatment of or radiotherapy for haematological malignancy Pregnant women and nursing mothers No informed consent from patient Known hyper sensitivity to bismuth or other tablet content Severe renal insufficiency with creatinin clearance below 25 ml/min. Patients receiving other treatment for protection of the mucous membrane except cryo treatment of the oral cavity (lumps of ice in the mouth) Other experimental treatment within past four weeks.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>haematology</keyword>
	<keyword>haematological</keyword>
	<keyword>hematology</keyword>
	<keyword>hematological</keyword>
	<keyword>malignancy</keyword>
	<keyword>lymphoma</keyword>
	<keyword>myeloma</keyword>
	<keyword>leukemia</keyword>
	<keyword>blood diseases</keyword>
	<keyword>malignant</keyword>
	<keyword>bismuth</keyword>
</DOC>